Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TERT | O14746 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | DTYMK | P23919 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18893940 | 0.86 | GPR119 (0.45) | ALDH1A1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL950278 | 0.86 | CHRM2 (0.48) | ALDH1A1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL24029890 | 0.82 | CHRM2 (0.44) | ALDH1A1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL6635750 | 0.81 | CHRM2 (0.55) | ALDH1A1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL12735270 | 0.81 | CHRM2 (0.55) | ALDH1A1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL31505409 | 0.81 | CHRM2 (0.55) | ALDH1A1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL15315922 | 0.81 | CHRM2 (0.55) | ALDH1A1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL17313885 | 0.81 | CHRM2 (0.55) | ALDH1A1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL578032 | 0.81 | CHRM2 (0.55) | ALDH1A1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL5604673 | 0.81 | CHRM2 (0.55) | ALDH1A1CHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503473-B2 | Triazolopyrimidine compounds and their use in treating cancer | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| CN-115028637-B | Triazolopyrimidine compounds and their use for the treatment of cancer | 迪哲(江苏)医药股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-11851432-B2 | Triazolopyrimidine compounds and their use in treating cancer | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-12-26 | — | — | US | disclosed |
| US-20230331761-A1 | Aryl Glucoside Derivative, Preparation Method Therefor And Application Thereof | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331761-A1 | Aryl Glucoside Derivative, Preparation Method Therefor And Application Thereof | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| EP-3640248-B1 | AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) | 2023-08-23 | — | — | EP | disclosed |
| EP-3640248-B1 | AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-7888352-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIRAMED LIMITED (GB) | 2011-02-15 | — | — | US | disclosed |
| US-20100234370-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| US-7750002-B2 | Pharmaceutical compounds | PIRAMED LIMITED (GB) | 2010-07-06 | — | — | US | disclosed |
| CN-101600720-A | Phosphoinositide 3-kinase inhibitor compounds and using method | HOFFMANN LA ROCHE (CH) | 2009-12-09 | — | — | CN | disclosed |
| EP-2114949-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-20080242665-A1 | 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-20080207611-A1 | Pharmaceutical compounds | PLRAMED LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| WO-2008070740-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| EP-1812445-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006046031-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503473-B2 | Triazolopyrimidine compounds and their use in treating cancer | ABCC4, ABCB1, SLC16A3 | ALDH1A1 205/4885CHRM2 3495/4885CHRM4 2383/4885 |
| US-20230331761-A1 | Aryl Glucoside Derivative, Preparation Method Therefor And Application Thereof | SLC5A1, SLC5A2, SLC10A1 | ALDH1A1 449/4885CHRM2 4157/4885CHRM4 4182/4885 |
| US-20100234370-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | ALDH1A1 2178/4885CHRM2 2135/4885CHRM4 2960/4885 |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ABCC4, ABCB1, SLC16A3 | ALDH1A1 205/4885CHRM2 3495/4885CHRM4 2383/4885 |
| US-11851432-B2 | Triazolopyrimidine compounds and their use in treating cancer | ABCC4, ABCB1, SLC16A3 | ALDH1A1 205/4885CHRM2 3495/4885CHRM4 2383/4885 |
| US-20080207611-A1 | Pharmaceutical compounds | PIK3CA, JAK2, PIK3R1 | ALDH1A1 2232/4885CHRM2 2162/4885CHRM4 2973/4885 |
| US-20080242665-A1 | 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; | PI4KA, DMPK, PDPK1 | ALDH1A1 2326/4885CHRM2 2845/4885CHRM4 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.